the changes in serum hdl- and ldl-cholesterol during the trial were associated ( p less than 0.02 and p less than 0.05 , respectively ) with the risk of coronary heart disease in the gemfibrozil group , but not in the placebo group .
C0018799
the
C0018787
heart